FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159336201> ?p ?o ?g. }

• W3159336201 endingPage "4669" @default.
• W3159336201 startingPage "4658" @default.
• W3159336201 abstract "Evaluate safety, tolerability, pharmacokinetics (PK) and target engagement (TE) of losmapimod in blood and muscle in facioscapulohumeral dystrophy (FSHD).This study included Part A: 10 healthy volunteers randomized to single oral doses of losmapimod (7.5 mg then 15 mg; n = 8) or placebo (both periods; n = 2); Part B: 15 FSHD subjects randomized to placebo (n = 3), or losmapimod 7.5 mg (n = 6) or 15 mg (n = 6); and Part C: FSHD subjects received open-label losmapimod 15 mg (n = 5) twice daily for 14 days. Biopsies were performed in FSHD subjects at baseline and Day 14 in magnetic resonance imaging-normal appearing (Part B) and affected muscle identified by abnormal short-tau inversion recovery sequence + (Part C). PK and TE, based on pHSP27:total HSP27, were assessed in muscle and sorbitol-stimulated blood.PK profiles were similar between healthy volunteers and FSHD subjects, with mean Cmax and AUC0-12 for 15 mg in FSHD subjects (Part B) of 85.0 ± 16.7 ng*h/mL and 410 ± 50.3 ng*h/mL, respectively. Part B and Part C PK results were similar, and 7.5 mg results were approximately dose proportional to 15 mg results. Dose-dependent concentrations in muscle (42.1 ± 10.5 ng/g [7.5 mg] to 97.2 ± 22.4 ng/g [15 mg]) were observed, with plasma-to-muscle ratio from ~0.67 to ~1 at estimated tmax of 3.5 hours postdose. TE was observed in blood and muscle. Adverse events (AEs) were mild and self-limited.Losmapimod was well tolerated, with no serious AEs. Dose-dependent PK and TE were observed. This study supports advancing losmapimod into Phase 2 trials in FSHD.Clinical trial identifier ToetsingOnline: NL68539.056.18 Nederlands Trials Register NL8000." @default.
• W3159336201 created "2021-05-10" @default.
• W3159336201 creator A5013002662 @default.
• W3159336201 creator A5034820865 @default.
• W3159336201 creator A5046374697 @default.
• W3159336201 creator A5056240427 @default.
• W3159336201 creator A5058668741 @default.
• W3159336201 creator A5065362371 @default.
• W3159336201 creator A5067041210 @default.
• W3159336201 creator A5072004949 @default.
• W3159336201 creator A5076335485 @default.
• W3159336201 creator A5078628655 @default.
• W3159336201 creator A5081121858 @default.
• W3159336201 creator A5081346831 @default.
• W3159336201 creator A5086423313 @default.
• W3159336201 creator A5088163706 @default.
• W3159336201 creator A5088182421 @default.
• W3159336201 creator A5090637756 @default.
• W3159336201 date "2021-05-14" @default.
• W3159336201 modified "2023-09-30" @default.
• W3159336201 title "Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement" @default.
• W3159336201 cites W1539898358 @default.
• W3159336201 cites W1965479467 @default.
• W3159336201 cites W2026556066 @default.
• W3159336201 cites W2086775164 @default.
• W3159336201 cites W2115013301 @default.
• W3159336201 cites W2117678288 @default.
• W3159336201 cites W2163350403 @default.
• W3159336201 cites W2258002262 @default.
• W3159336201 cites W2725014645 @default.
• W3159336201 cites W2897468238 @default.
• W3159336201 cites W2951577426 @default.
• W3159336201 cites W2975218243 @default.
• W3159336201 cites W2987819628 @default.
• W3159336201 cites W3037746690 @default.
• W3159336201 doi "https://doi.org/10.1111/bcp.14884" @default.
• W3159336201 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33931884" @default.
• W3159336201 hasPublicationYear "2021" @default.
• W3159336201 type Work @default.
• W3159336201 sameAs 3159336201 @default.
• W3159336201 citedByCount "13" @default.
• W3159336201 countsByYear W31593362012022 @default.
• W3159336201 countsByYear W31593362012023 @default.
• W3159336201 crossrefType "journal-article" @default.
• W3159336201 hasAuthorship W3159336201A5013002662 @default.
• W3159336201 hasAuthorship W3159336201A5034820865 @default.
• W3159336201 hasAuthorship W3159336201A5046374697 @default.
• W3159336201 hasAuthorship W3159336201A5056240427 @default.
• W3159336201 hasAuthorship W3159336201A5058668741 @default.
• W3159336201 hasAuthorship W3159336201A5065362371 @default.
• W3159336201 hasAuthorship W3159336201A5067041210 @default.
• W3159336201 hasAuthorship W3159336201A5072004949 @default.
• W3159336201 hasAuthorship W3159336201A5076335485 @default.
• W3159336201 hasAuthorship W3159336201A5078628655 @default.
• W3159336201 hasAuthorship W3159336201A5081121858 @default.
• W3159336201 hasAuthorship W3159336201A5081346831 @default.
• W3159336201 hasAuthorship W3159336201A5086423313 @default.
• W3159336201 hasAuthorship W3159336201A5088163706 @default.
• W3159336201 hasAuthorship W3159336201A5088182421 @default.
• W3159336201 hasAuthorship W3159336201A5090637756 @default.
• W3159336201 hasBestOaLocation W31593362011 @default.
• W3159336201 hasConcept C112705442 @default.
• W3159336201 hasConcept C126322002 @default.
• W3159336201 hasConcept C126894567 @default.
• W3159336201 hasConcept C142724271 @default.
• W3159336201 hasConcept C197934379 @default.
• W3159336201 hasConcept C204787440 @default.
• W3159336201 hasConcept C22979827 @default.
• W3159336201 hasConcept C27081682 @default.
• W3159336201 hasConcept C2778375690 @default.
• W3159336201 hasConcept C71924100 @default.
• W3159336201 hasConcept C90924648 @default.
• W3159336201 hasConcept C98274493 @default.
• W3159336201 hasConceptScore W3159336201C112705442 @default.
• W3159336201 hasConceptScore W3159336201C126322002 @default.
• W3159336201 hasConceptScore W3159336201C126894567 @default.
• W3159336201 hasConceptScore W3159336201C142724271 @default.
• W3159336201 hasConceptScore W3159336201C197934379 @default.
• W3159336201 hasConceptScore W3159336201C204787440 @default.
• W3159336201 hasConceptScore W3159336201C22979827 @default.
• W3159336201 hasConceptScore W3159336201C27081682 @default.
• W3159336201 hasConceptScore W3159336201C2778375690 @default.
• W3159336201 hasConceptScore W3159336201C71924100 @default.
• W3159336201 hasConceptScore W3159336201C90924648 @default.
• W3159336201 hasConceptScore W3159336201C98274493 @default.
• W3159336201 hasIssue "12" @default.
• W3159336201 hasLocation W31593362011 @default.
• W3159336201 hasLocation W31593362012 @default.
• W3159336201 hasOpenAccess W3159336201 @default.
• W3159336201 hasPrimaryLocation W31593362011 @default.
• W3159336201 hasRelatedWork W1830687917 @default.
• W3159336201 hasRelatedWork W2064759457 @default.
• W3159336201 hasRelatedWork W2074207917 @default.
• W3159336201 hasRelatedWork W2319060667 @default.
• W3159336201 hasRelatedWork W2329478898 @default.
• W3159336201 hasRelatedWork W2789708638 @default.
• W3159336201 hasRelatedWork W3178697376 @default.
• W3159336201 hasRelatedWork W4220955662 @default.

• next